Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Preparing compound containing saccharide radical
Patent
1997-07-31
1998-11-24
Saunders, David
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Preparing compound containing saccharide radical
435 76, 435 71, 435 793, 53038826, 53038825, 5303893, 53038885, 5303897, G01N 33573, G01N 33574, G01N 33577, C07K 1640
Patent
active
058405011
ABSTRACT:
A method for determining the complexed forms of immunologically determinable prostate specific antigen (cPSA) in a blood sample, e.g., by two-site immunometric assays, in which the blood sample is treated to render free PSA (fPSA)immunologically nondetectable. A particularly preferred immunometric assay method employs three anti-PSA antibodies: an antibody that binds to both cPSA and fPSA (anti-tPSA), a second anti-tPSA antibody which is characterized by the unique property that binding to fPSA is blocked by binding of fPSA-specific antibodies, and a third antibody which is a fPSA-specific antibody. Thus, binding of the fPSA-specific antibody to PSA in the sample allows only cPSA to be measured in the immunometric assay. Measurement of cPSA blood levels has been found to provide a method for aiding in the diagnosis and monitoring of prostate cancer that is highly sensitive and specific, and eliminates the need for a significant number of patients to undergo unnecessary prostate biopsy.
REFERENCES:
patent: 5501983 (1996-03-01), Lilja et al.
patent: 5599677 (1997-02-01), Dowell et al.
Oesterling, JE et al. J. Urology. 154:1090-1095, Sep. 1995.
J. Leinonen et al: "Complex Formation between PSA isoenzymes and protease inhibitors." The Journal of Urology, vol. 155, No. 3, Mar. 1996, pp. 1099-1103.
Kramer BS et al: "Prostate Cancer Screening: What We Know and What We Need to Know." Annals of Internal Medicine, vol. 119, No. 9, 1 Nov. 1993, pp. 914-923.
Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan 0. A Complex between prostate-specific antigen and .alpha.-121-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51:222-226.
Zhou AM, Tewari PC, Bluestein BL, Caldwell GW, Larsen FL. Multiple forms of prostate-specific antigen in serum: differences in immunorecognition by monoclonal and polyclonal assays. Clin Chem 1993; 39:2483-2491.
Leinonen J, Lovgren T, Vornanen T, Stenman UH. Double-label time-resolved immunoflurometric of prostate-specific antigen and its complex with .alpha..sub.1 -antichymotrypsin Clin Chem 1993; 39:2098-2103.
Christensson A, Bjork T, Nilsson 0, Dahlen U, Matikainen MT, Cockett AT, Abrahamsson PA. Serum prostate specific antigen complexed with .alpha..sub.1 -antichymotrypsin as an indicator of prostate cancer. J. Urol 1993; 159:100-105.
Lilja H. Significance of differrent molecular forms of serum PSA. The free, noncomplexed forms of PSA versus that complexed to .alpha..sub.1 -antichymotrypsin. Urol Clin North Am 1993; 20(4):681-686.
Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson 0, Pettersson K & Lovgren T. Prostate-specific antigen in human serum occurs predominantly in complex with alpha-antichymotrypsin. Clin Chem 1991; 37:1618-1625.
Bjork T, Hulkko S, Bjartell A, Santagnese AD, Abrahamsson PA, Lilja H. .alpha..sub.1 -antichymotrrypsin production in PSA-producing cells is common in prostate cancer but rate in benign prostatic hyperplasia. Urology 1994; 43:427-434.
Pettersson K, Piironen T, Seppala M, Liukkonen L, Christensson A, Matikainen MT, Suonpaa M, Lovgren T, Lilja H. Free and complexed prostate-specific antigen (PSA): in vitro stability, epitope map, and development of immunoflurometric assays for specicifc and sensitive detection of free PSA and PSA-.alpha..sub.1 -antichymotrypsin complex Clin chem 1995; 41:1480-1488.
Wu JT, Wilson L, Zhang P, Meikle AW, Stephenson R. Correlation of serum concentraitons of PSA-ACT complex with total PSA in random and serial specimens from patients with BPH and prostate cancer. J. Clin Lab Anal 1995; 9:15-24.
Mitrunen K, Pettersson K, Piironen T, Bjork T, Lilja H, Lovgren T. (1995) Duel label one-step immunoassay for simultaneous measurement of free and total prospate specific antigen concentraiton and ratios in serum. Clin chem 1995 41(8):1115-1120.
Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, Nadler RB. Evaluation of percentage of free serum prostage-specific antigen to improve specificity of prostate cancer screening. JAMA 1995; 274(15):1214-1220.
Prestigiacomo AF, Stamey TA. Clinical usefulness of free and complexed PSA. Scan J. Clin Invest 1995; 55Supp1221:32-34.
Wang TJ , Hill TM, Sokoloff RL, Frankenne F, Rittenhouse HG, Wolfert RL. Duel monoclonal antibody immunoassay for free prostate-specific antigen. Prostate 1996; 28:10-16.
Jung K, Stephan C, Lein M, Henkne W, Schnorr D, Brux B, Schurenkamper P, Loening SA. Analytical performance and clinical validity of two free prostate-specific antigen assays compared. Clin Chem. 1996; 42(7):1026-1033.
Wang TJ, Hill T, Sokoloff R, Frankenne F, Wolfert R and Rittenhouse H. Monoclonal antibody sandwich immunoassay to quantitate free PSA in benign hyperplasia and prostate cancer. Poster presentation at 1994 ISOBM meeting.
Chan D, Kelley CA, Partin AW, Linton J, Want TJ, Sokoloff RL, Rittenhouse HG, and Wolfert RL. Clin Chem (1996) 42(6):S255.
Wang TJ, Linton HJ, Payne J, Liu RS, Kuus-Reichel K, Rittenhouse HG, Kelley C, Cox J, Chan DW, and Wolfert RL. Development of monoclonal antibodies specific for the PSA-ACT complex and their incorporation into an immunoassay. Clin Chem (1997); 43(6):S225.
Zhang P and Wu JT. Development of an immunoassay for the PSA-ACT complex in serum without interference of non-specific adsorption. Clin Chem (1997) 43(6):S236.
Bjork T, Bjartell A, Abrahamsson PA, Hulkko S, Di Sant'agnese A, Lilja H. .alpha..sub.1 -antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. Urol 1994; 43(4):427-434.
Carter HB, Pearson JD, Metter J, Brant LJ, Chan DW Andres R, Fozard JL and Walsh PC. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267(16)2215.
Allard William Jeffrey
Yeung Kwok K.
Zhou Zeqi
Bayer Corporation
Klawitter A. L.
Saunders David
VanderVegt F. Pierre
LandOfFree
Determination of cPSA does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Determination of cPSA, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Determination of cPSA will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1700614